World Fair for Organic Wines: the Trade Fair Will Be Back Again in Force In 2022!
14.12.2021 17:07:00 EET | Business Wire | Press release
Millésime Bio has become, over the years, the number one marketplace for professionals in the organic wine, cider, beer and spirits industries. With its digital session on 17 and 18 January 2022 and its physical fair on 24, 25 and 26 January 2022 at Montpellier Exhibition Centre, the World Fair for Organic Wines will be the first major international wine fair since the COVID crisis, a symbol that the recovery is underway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005696/en/
(Photo: Gilles Lefrancq/Millésime Bio)
MILLESIME BIO 2022: A DOUBLE EVENT
Millésime Bio, traditionally the first wine, cider, beer and spirits trade fair of the year, will take place in two stages for this 2022 edition. A double event that will guarantee all professionals their participation while taking into account the sanitary constraints imposed in France and abroad.
The World fair for organic wines will start on 17 January for two days. Based on the model of the 2021 100% digital edition, more than 450 exhibitors and several thousand visitors will be able to exchange information and make initial contacts prior to the physical fair. On this occasion, visitors will discover in preview the medal-winners list of the Challenge Millésime Bio 2022 contest. From Monday 24 January to Wednesday 26 January, the physical fair will be an opportunity to get back to live tastings and meetings.
12/01/2022 - CHALLENGE MILLESIME BIO 2022
Every year, SudVinBio organises the largest international organic wine contest before the fair: the Challenge Millésime Bio contest. This year, the 15th edition of the contest will take place on Wednesday 12 January 2022.
NEW: Challenge Millésime Bio is opening up to international organic beers. The contest team will be accompanied by the SNBI (French National Union for Independent Breweries) to set up this tasting.
The medal-winning wines and beers will be available for tasting during the 3 days of the fair, in an area dedicated to the Challenge Millésime Bio.
More than 1,400 exhibitors from 20 countries will be there, in the heart of the number one organic vineyard in France, and will present about 40% of the French organic wine offer and a wide range of the international offer. This renewed enthusiasm consolidates Millésime Bio's position as the key marketplace that will set the trend for future trade fairs in a post health crisis context.
In parallel with the meetings with exhibitors, visitors will be able to attend a 2-day programme of conferences and Master Classes led by experts. The programme will include the results of a European IPSOS/Millésime Bio study on organic wine consumption habits.
"The Millésime Bio trade fair will welcome you from 17 January, to start with in its digital format. Following the success of last year's launch, we have perfected our online platform this year, in order to programme it a few days before our traditional physical event, which is back at last!
More than ever, we are listening to visitors and exhibitors to optimise the efficiency of this key event for buyers in the organic wine and spirits sector. Thus, a special place is reserved this year for the brewery and cider industries.”
Jeanne Fabre, President of the Millésime Bio Commission
ABOUT
MILLÉSIME BIO IS ORGANISED BY SUDVINBIO, OCCITANIA TRADE ASSOCIATION OF ORGANIC VINTNERS
SudVinBio is a non-profit association created in 1991. It is an interprofessional organisation representing producers (independent wineries and cooperatives) and merchants of organic wines in the Occitania region, France’s number one organic wine region. SudVinBio represents around 70% of the regional production of certified organic wines at the end of 2020 (around 700 000 hl). It orchestrates promotional and communication activities, protects the interests of its members, provides support for research and development as well as advisory services to its members.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005696/en/
Contact information
PRESS CONTACT
Anaïs Marchand & Fanny Courtial
+33 (0)4 72 07 42 41
fanny.courtial@clairdelune.fr – www.clairdelune.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie10.9.2026 14:02:00 EEST | Press release
One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, today announced support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910763012/en/ Triple-negative breast cancer (TNBC) represents approximately 15–20% of breast cancer cases. Patients face high relapse rates, rapid disease progression and limited treatment options, while clinicians still lack reliable biomarkers to predict which patients will respond to immunotherapy or chemotherapy combinations. Current diagnostic approaches average signals across mil
New WSJ Intelligence Survey Highlights the Human Skills Companies Must Protect as AI Enters the Workplace10.9.2026 14:00:00 EEST | Press release
Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today unveiled The Cognition Index Research Report, a comprehensive study exploring the evolving role of human cognition in an AI-driven workplace. Surveying more than 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil, the report reveals that while business professionals are increasingly optimistic about AI’s role in improving decision-making, they continue to see human judgment, ethics, critical thinking and empathy as essential capabilities that must be actively protected and developed as AI becomes embedded in workplace workflows. “Human cognition is a bit like a muscle: use it or lose it,” says Moira Gilchrist, Chief Global Communications Officer at Philip Morris International. “AI can help us work more efficiently, but we need to be careful not to outsource ou
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training10.9.2026 13:35:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive application process based on their expertise and proven ability to develop and deliver high-quality training at scale. They will remain independent training and education providers, retaining ownership and control of their training programs, content, faculty selection, and educational design, consistent with ACCME Standards for Integrity and Independe
Compass Pathways to Participate in Investor Conferences the Week of September 14 th10.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on September 15, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY: Fireside chat at 11:30am ET on September 16, 2026 Deutsche Bank’s 2026 Healthcare Summit – New York, NY: Fireside chat at 11:00am ET on September 17, 2026 A live audio webcast of the fireside chats will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlockin
GasEntec Announces New Ownership Structure, Accelerating Next Phase of Global Growth10.9.2026 12:00:00 EEST | Press release
GasEntec Holdings Inc., a global LNG technology and assets company, today announced a new ownership structure designed to accelerate GasEntec’s next phase of growth and expand the commercialization of its proprietary LNG technologies and solutions. A consortium led by the Groupe Mimran has acquired a majority stake in GasEntec Holdings Inc., the US holding company, supporting GasEntec’s global growth. Under the new structure, GasEntec Holdings is the parent company of GasEntec’s South Korean operating business. Prior shareholders have exited in full. GasEntec’s customer relationships, contracts, engineering organization and ongoing global operations remain unchanged. GasEntec will continue to operate independently, with its technology development, engineering and operations centered in South Korea and an expanding commercial presence across global markets. The new structure provides GasEntec with additional capital and strategic resources to build on its history of LNG innovation and p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom